Figure 1. Kaplan–Meier curves estimating cumulative probability of dolutegravir (DTG)‐discontinuation regardless of the reason (A,B), for toxicity (C,D) and for neuropsychiatric adverse events (E,F) and the cumulative probability of virological failure (G,H) in antiretroviral therapy (ART)‐naïve and treatment‐experienced (TE) groups.
